Claris Bio is a clinical stage biotech company developing a first-in-class drug for limbal stem cell deficiency, an ophthalmology disorder that can cause pain, corneal irritation and loss of visual function. ​

Limbal stem cell deficiency is a large (~50,000 US persons) orphan indication with no disease modifying therapeutic options—treatment is limited to surgical options which help control disease but do not alter its course. Claris has developed a first in class eye drop which addresses the root cause of limbal stem cell deficiency and rejuvenates the ocular surface. In phase 2 studies, Claris demonstrated impressive improvements in corneal clarity and restoration of visual function.